Adaptimmune Therapeutics Plc (ADAP)

10.44
0.54 4.92
NASDAQ : Health Technology
Prev Close 10.98
Open 10.93
Day Low/High 10.36 / 10.95
52 Wk Low/High 4.82 / 14.62
Volume 535.15K
Avg Volume 382.60K
Exchange NASDAQ
Shares Outstanding 94.29M
Market Cap 1.05B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.

Interesting ADAP Put And Call Options For December 21st

Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Adaptimmune Therapeutics Reaches Analyst Target Price

In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $13.40, changing hands for $13.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

ADAP Crosses Above Average Analyst Target

ADAP Crosses Above Average Analyst Target

In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $10.20, changing hands for $10.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Adaptimmune Announces Responses In Second Solid Tumor Indication With NY-ESO SPEAR T-cells

Adaptimmune Announces Responses In Second Solid Tumor Indication With NY-ESO SPEAR T-cells

Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

First Week of February 16th Options Trading For Adaptimmune Therapeutics (ADAP)

First Week of February 16th Options Trading For Adaptimmune Therapeutics (ADAP)

Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

Adaptimmune Announces Two Manufacturing Achievements On Its Way To Become The First Fully Integrated TCR T-cell Therapy Company

Adaptimmune Announces Two Manufacturing Achievements On Its Way To Become The First Fully Integrated TCR T-cell Therapy Company

Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity

Adaptimmune Therapeutics Enters Oversold Territory (ADAP)

Adaptimmune Therapeutics Enters Oversold Territory (ADAP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Adaptimmune Marks Official Opening Of U.K. Headquarters

Adaptimmune Marks Official Opening Of U.K. Headquarters

Flagship Facility is new Base for U.K. Research and Development Operations

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADAP, CTRP, DCO, GRPN, KMT, NYMT, PBF, SAM, SFUN, SPAR, TPX Downgrades: AEGN, BATRA, BATRK, CMT, FNSR, KEM, KOF, LL, LQ, MX, NFG, NLS Initiations: DFIN, DZSI Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D+ (Sell)